New hope for easing the exhaustion of leukemia
NCT ID NCT02131584
Summary
This study is testing whether a drug called ruxolitinib can help reduce severe fatigue in people with chronic lymphocytic leukemia (CLL) who are not yet receiving standard anti-cancer therapy. About 10 participants will take the pill twice daily for up to two years. The main goal is to see if the treatment significantly improves patients' energy levels and overall symptom burden.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.